Understanding Hallucinations (Part I)

Understanding Hallucinations (Part I) - Phenomenology and Cognition

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01907568

Acronym

UH-1

Enrollment

700

Registered

2013-07-25

Start date

2013-06-30

Completion date

2018-01-31

Last updated

2016-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallucinations, No Hallucinations

Brief summary

Psychotic symptoms (hallucinations and delusions) are present in several psychiatric and neurological disorders as well as in the general population. Effective treatment strategies for these symptoms in all patients are lacking and treatment-response can presently not be predicted. To date, the exact pathophysiological mechanism of these symptoms remains unknown. By investigating (subtypes) of hallucinations and delusions in all populations, a common pathway may be found, leading to more effective treatment options. Alternatively, different subtypes may be associated with different pathophysiological mechanisms.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* age \> 18 years * mentally competent * in case of delirium: family member able to give informed consent * Individuals with hallucinations will have to experience at least one episode of hallucinations over the last month. * Individuals without hallucinations: no current hallucinations and a history of maximum 1 episode of hallucinations with a maximum duration of 1 week, at least two years ago.

Exclusion criteria

* Age \<18) * Participants that cannot read, speak or understand Dutch * For all included diagnostic groups except delirium: Mentally incompetent individuals who are not capable to provide informed consent, as determined by their treating physician.

Design outcomes

Primary

Measure	Time frame
The number of clusters of patients with shared symptom profiles as determined by latent class analysis, and the difference in scores on cognitive assessment between these identified clusters.	Three years

Secondary

Measure	Time frame
The internal consistency, test-retest reliability, inter-rater reliability, criterion validity and construct validity of a newly developed questionnaire.	Two years
The difference in scores on cognitive assessment between participant groups with and without psychotic symptoms.	Three years

Countries

Netherlands

Contacts

Primary ContactMascha M.J. Linszen, MD

m.m.j.linszen@umcutrecht.nl+31887557468

Backup ContactSophie M. Heringa, PhD

s.m.heringa@umcutrecht.nl

Outcome results